Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

161. The effect of statins pretreatment on major adverse cardiac events in Asian patients undergoing percutaneous coronary interventions

The effect of statins pretreatment on major adverse cardiac events in Asian patients undergoing percutaneous coronary interventions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

162. Statins exposure and risk of hepatocellular carcinoma in population infected with hepatitis viruses: a systematic review

Statins exposure and risk of hepatocellular carcinoma in population infected with hepatitis viruses: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

163. Statins as adjunctive chemotherapy agents: a systematic review and meta-analysis

Statins as adjunctive chemotherapy agents: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

164. Proprotein convertase subtilisin/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis

Proprotein convertase subtilisin/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2017 PROSPERO

165. Preoperative statin therapy and acute kidney injury following cardiac surgery: a systematic review and meta-analysis of randomized controlled trials

Preoperative statin therapy and acute kidney injury following cardiac surgery: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO

166. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews

Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

167. Statins and erectile dysfunction: a systematic review and meta-analysis

Statins and erectile dysfunction: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

168. The impact of statins on abdominal aortic aneurysm growth, rupture, and perioperative outcomes: a systematic review and meta-analysis

The impact of statins on abdominal aortic aneurysm growth, rupture, and perioperative outcomes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

169. Statins add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis

Statins add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

170. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a systematic review and meta-analysis of randomised controlled trials

Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2017 PROSPERO

171. Systematic review of the effect of statins and antiplatelet drugs on plasma D-dimer levels

Systematic review of the effect of statins and antiplatelet drugs on plasma D-dimer levels Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

172. Does statin administration affect prognosis or mortality after cancer diagnosis? Systematic review and meta-analysis

Does statin administration affect prognosis or mortality after cancer diagnosis? Systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

173. Effect of statins and currently recommended non-statin LDL-C lowering medications on clinical outcomes in secondary prevention patients: a meta-analysis of randomized trials

Effect of statins and currently recommended non-statin LDL-C lowering medications on clinical outcomes in secondary prevention patients: a meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2017 PROSPERO

174. Perspective on Trends in Statin Use Full Text available with Trip Pro

Perspective on Trends in Statin Use 27842177 2018 11 13 2380-6591 2 1 2017 Jan 01 JAMA cardiology JAMA Cardiol Perspective on Trends in Statin Use. 11-12 10.1001/jamacardio.2016.4710 Weintraub William S WS Christian Care Health System, Newark, Delaware. eng U54 GM104941 GM NIGMS NIH HHS United States Journal Article United States JAMA Cardiol 101676033 2016 11 15 6 0 2016 11 15 6 0 2016 11 15 6 0 ppublish 27842177 2583423 10.1001/jamacardio.2016.4710 PMC5621636 NIHMS863753 Health Aff (Millwood

2017 JAMA cardiology

175. Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins

Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins Article Text Commentary: General medicine Unblinded ASCOT study results do not rule out

2017 Evidence-Based Medicine

176. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Full Text available with Trip Pro

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes.Posttrial follow-up

2017 JAMA cardiology Controlled trial quality: predicted high

177. Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study Full Text available with Trip Pro

Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study Disease-modifying drugs are not yet available for the management of chronic obstructive pulmonary disease (COPD). HMG-CoA reductase inhibitors (statins) have anti-inflammatory properties and are therefore being considered for use in the management of COPD.Our objective was to examine the association between statin use and COPD-specific outcomes in a real-world setting.This was a retrospective (...) longitudinal dynamic cohort study that used Medicaid claims data from multiple years (2005-2008) to identify patients with newly diagnosed COPD. Statin therapy was determined from the prescription drug file using National Drug Codes (NDCs). COPD-specific outcomes such as hospitalizations and emergency room and outpatient visits were identified based on a primary diagnosis of COPD. Multivariable logistic regressions with inverse probability treatment weights (IPTWs) were used to examine the relationship

2016 Drugs - real world outcomes

178. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis Full Text available with Trip Pro

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin (...) of the intention-to-treat populations in the TCZ-IV and TCZ-SC studies, and results were stratified by concomitant statin use.Data from this descriptive, retrospective, pooled analysis indicated that statins can stabilize lipid levels without a clinically significant increase in adverse events. Approximately 30% of patients in the TCZ treatment arms who never received a statin demonstrated a shift in low-density-lipoprotein cholesterol (LDL-C) from <130 mg/dl at baseline to ≥130 mg/dl at 2 years. However

2016 Rheumatology and therapy Controlled trial quality: uncertain

179. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence Full Text available with Trip Pro

Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence 27838724 2016 12 13 2018 11 13 1538-3598 316 19 2016 Nov 15 JAMA JAMA Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. 1971-1972 10.1001/jama.2016.15212 Gurwitz Jerry H JH Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester, Massachusetts2Division of Geriatric Medicine

2016 JAMA

180. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment (...) of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD

2016 JAMA